Compare OpGen, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 19.59% and Operating profit at 18.89% over the last 5 years
3
With ROE of 67.37%, it has a attractive valuation with a 18.16 Price to Book Value
4
Majority shareholders : Mutual Funds
5
Market Beating performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
76.49%
0%
76.49%
6 Months
24699900.0%
0%
24699900.0%
1 Year
814.81%
0%
814.81%
2 Years
394.99%
0%
394.99%
3 Years
1664.29%
0%
1664.29%
4 Years
3059.38%
0%
3059.38%
5 Years
737.29%
0%
737.29%
OpGen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.59%
EBIT Growth (5y)
18.89%
EBIT to Interest (avg)
-8.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.66%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
18.16
EV to EBIT
27.72
EV to EBITDA
26.97
EV to Capital Employed
18.24
EV to Sales
20.49
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
65.81%
ROE (Latest)
67.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 2 Schemes (0.13%)
Foreign Institutions
Held by 4 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
0.00
4.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-0.70
3.40
-120.59%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.60
3.50
-117.14%
Operating Profit Margin (Excl OI)
0.00%
850.70%
-85.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -100.00% vs 0.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -117.14% vs 975.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5.20
3.40
52.94%
Operating Profit (PBDIT) excl Other Income
0.60
-14.40
104.17%
Interest
0.00
1.80
-100.00%
Exceptional Items
11.50
-2.00
675.00%
Consolidate Net Profit
12.00
-32.70
136.70%
Operating Profit Margin (Excl OI)
77.00%
-4,589.50%
466.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 52.94% vs 30.77% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 136.70% vs 12.33% in Dec 2023
About OpGen, Inc. 
OpGen, Inc.
Miscellaneous
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Company Coordinates 
Company Details
708 Quince Orchard Rd Ste 205 , GAITHERSBURG MD : 20878-1793
Registrar Details






